within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01G_AminoglycosideAntibacterials.J01GB05_Neomycin;

model Neomycin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.01,
    Cl = 1.4999999999999998e-06,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.00025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0016666666666666668,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Neomycin</td></tr><tr><td>ATC code:</td><td>J01GB05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.25</td><td>L</td></tr>
    <tr><td>clearance:</td><td>90</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Neomycin is an aminoglycoside antibiotic primarily used for the treatment of infections caused by susceptible bacteria and for bowel sterilization before elective surgery. It is not significantly absorbed from the gastrointestinal tract and is currently limited in systemic therapeutic use due to potential nephrotoxicity and ototoxicity. Most use nowadays is topical or oral (non-absorbed) for bowel decontamination.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult patients; oral administration; due to negligible systemic absorption data is limited. Estimates based on drug characteristics and review literature.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01GB05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Neomycin;
